Cargando…
Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
BACKGROUND: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139121/ https://www.ncbi.nlm.nih.gov/pubmed/34040779 http://dx.doi.org/10.4081/mrm.2021.737 |
_version_ | 1783695941980651520 |
---|---|
author | Coloretti, Irene Busani, Stefano Biagioni, Emanuela Venturelli, Sophie Munari, Elena Sita, Marco DallAra, Lorenzo Tosi, Martina Clini, Enrico Tonelli, Roberto Fantini, Riccardo Mussini, Cristina Meschiari, Marianna Guaraldi, Giovanni Cossarizza, Andrea Alfano, Gaetano Girardis, Massimo |
author_facet | Coloretti, Irene Busani, Stefano Biagioni, Emanuela Venturelli, Sophie Munari, Elena Sita, Marco DallAra, Lorenzo Tosi, Martina Clini, Enrico Tonelli, Roberto Fantini, Riccardo Mussini, Cristina Meschiari, Marianna Guaraldi, Giovanni Cossarizza, Andrea Alfano, Gaetano Girardis, Massimo |
author_sort | Coloretti, Irene |
collection | PubMed |
description | BACKGROUND: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit. METHODS: The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching. RESULTS: Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission. CONCLUSIONS: Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation. |
format | Online Article Text |
id | pubmed-8139121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-81391212021-05-25 Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study Coloretti, Irene Busani, Stefano Biagioni, Emanuela Venturelli, Sophie Munari, Elena Sita, Marco DallAra, Lorenzo Tosi, Martina Clini, Enrico Tonelli, Roberto Fantini, Riccardo Mussini, Cristina Meschiari, Marianna Guaraldi, Giovanni Cossarizza, Andrea Alfano, Gaetano Girardis, Massimo Multidiscip Respir Med Original Research Article BACKGROUND: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit. METHODS: The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching. RESULTS: Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission. CONCLUSIONS: Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation. PAGEPress Publications, Pavia, Italy 2021-05-17 /pmc/articles/PMC8139121/ /pubmed/34040779 http://dx.doi.org/10.4081/mrm.2021.737 Text en Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0). |
spellingShingle | Original Research Article Coloretti, Irene Busani, Stefano Biagioni, Emanuela Venturelli, Sophie Munari, Elena Sita, Marco DallAra, Lorenzo Tosi, Martina Clini, Enrico Tonelli, Roberto Fantini, Riccardo Mussini, Cristina Meschiari, Marianna Guaraldi, Giovanni Cossarizza, Andrea Alfano, Gaetano Girardis, Massimo Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study |
title | Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study |
title_full | Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study |
title_fullStr | Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study |
title_full_unstemmed | Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study |
title_short | Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study |
title_sort | effects of cytokine blocking agents on hospital mortality in patients admitted to icu with acute respiratory distress syndrome by sars-cov-2 infection: retrospective cohort study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139121/ https://www.ncbi.nlm.nih.gov/pubmed/34040779 http://dx.doi.org/10.4081/mrm.2021.737 |
work_keys_str_mv | AT colorettiirene effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT busanistefano effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT biagioniemanuela effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT venturellisophie effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT munarielena effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT sitamarco effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT dallaralorenzo effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT tosimartina effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT clinienrico effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT tonelliroberto effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT fantiniriccardo effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT mussinicristina effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT meschiarimarianna effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT guaraldigiovanni effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT cossarizzaandrea effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT alfanogaetano effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy AT girardismassimo effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy |